Literature DB >> 21278438

The biological framework: translational research from bench to clinic.

Yosef Yarden1.   

Abstract

The understanding of cellular signaling pathways in malignant tumors is an important aspect of cancer research and modern targeted therapy strategies. Growth factors and their receptors in particular are critical to modern cancer therapy research, because these factors control all phases of tumor development and metastasis. Most importantly, growth factors are responsible for cell survival under cytotoxic drugs and radiotherapy. These growth factor signaling pathways are composed of complex networks that have adapted to efficiently respond to certain disturbances, such as a single agent that targets one aspect of the pathway. Meanwhile, multiple insults to the pathway, such as combination therapy regimens, are known to be effective in shutting down these pathways and, consequently, killing the tumor cell. Research is currently under way to find new ways to exploit fragile aspects of oncogenic networks, such as uncommon, multiple perturbations that target essential hubs through immunotherapy, combinations of antibodies, heat shock protein inhibitors, or novel drug combinations. Complex growth factor signaling networks and novel methods to shut down these networks are described within a framework of engineering and mathematical concepts.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21278438     DOI: 10.1634/theoncologist.2011-S1-23

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  3 in total

Review 1.  Next-generation sequencing and personalized genomic medicine in hepatobiliary malignancies.

Authors:  Arturo Loaiza-Bonilla; Emma E Furth; Jennifer Jd Morrissette
Journal:  Hepat Oncol       Date:  2015-11-11

2.  3D super-resolution imaging with blinking quantum dots.

Authors:  Yong Wang; Gilbert Fruhwirth; En Cai; Tony Ng; Paul R Selvin
Journal:  Nano Lett       Date:  2013-10-10       Impact factor: 11.189

3.  Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.

Authors:  Arturo Loaiza-Bonilla; Erica Clayton; Emma Furth; Mark O'Hara; Jennifer Morrissette
Journal:  Ecancermedicalscience       Date:  2014-11-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.